StreetInsider.com News Articles

Gilead Sciences (GILD) PT Raised to $185 at Jefferies

Fri, 23 Oct 2026 04:23:01 -0400

Jefferies analyst Akash Tewari raised the price target on Gilead Sciences (NASDAQ: GILD) to $185.00 (from $184.00) while maintaining a Buy rating.

The analyst comments "GILD is acquiring PepStar Therapeutics' Ph1 oral anti-IL-23 (HCXT-2001), for $1.275Bn in cash. We like the deal given: 1) this allows GILD to pursue an oral a4b7 + IL-23 combo; 2) POC data from ABBV-466 shows that a4b7 + IL-23 combo may offer the best clinical remission in pts w/ prior advanced tx; and 3) HCXT-2001's preclinical PK looks favorable vs icotrokinra (JNJ oral IL-23) Bottom line: GILD is acquiring oral anti-IL23 HCXT-2001 from PepStar for

Gilead Sciences (GILD) PT Raised to $185 at Jefferies

Fri, 23 Oct 2026 04:23:01 -0400

Jefferies analyst Akash Tewari raised the price target on Gilead Sciences (NASDAQ: GILD) to $185.00 (from $184.00) while maintaining a Buy rating.

Gilead to buy oral IBD drug candidate for $1.275 billion

Thu, 22 Oct 2026 16:05:33 -0400

Gilead Sciences (NASDAQ: GILD) has agreed to acquire an oral IL-23 receptor inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a privately held clinical-stage biotechnology company, for $1.275 billion in upfront cash.

HCXT-2001 is an investigational oral macrocyclic peptide inhibitor of IL-23R currently in Phase 1 clinical trials. The compound targets immune-mediated inflammatory diseases, including inflammatory bowel disease (IBD) and potentially psoriasis. Its safety and efficacy have not been established, and it has not received regulatory approval.

The transaction grants Gilead worldwide rights to the IL-23R inhibitor program. Closing is expected in the fourth quarter of 2026, subject to customary

Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD

Thu, 22 Oct 2026 16:05:00 -0400

-- Clinical Program Adds a Potentially Differentiated Oral Peptide IL-23 Receptor Inhibitor to Gilead’s Inflammation Portfolio --

-- HCXT-2001 Has Potential as a Monotherapy or in Combination with Other Gilead Programs to Address Unmet Needs in Immune-Mediated Inflammatory Diseases --

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has entered into a definitive agreement to acquire an oral IL-23R inhibitor program, including lead asset HCXT-2001, from PepStar Therapeutics Limited, a privately held, clinical-stage biotechnology company.

Key Highlights

HCXT-2001 is an investigational, clinical-stage, oral, macrocyclic peptide inhibitor of IL-23R with an extended half-life, offering

Gilead to Acquire Investigational Oral IL-23R Inhibitor HCXT-2001, Strengthening Its Inflammation Pipeline in IBD

Thu, 22 Oct 2026 16:05:00 -0400

-- Clinical Program Adds a Potentially Differentiated Oral Peptide IL-23 Receptor Inhibitor to Gilead’s Inflammation Portfolio --

-- HCXT-2001 Has Potential as a Monotherapy or in Combination with Other Gilead Programs to Address Unmet Needs in Immune-Mediated Inflammatory Diseases --

Key Highlights

HCXT-2001 is an investigational, clinical-stage, oral, macrocyclic peptide inhibitor of IL-23R with an extended half-life, offering

Gilead to present 21 abstracts on rare liver diseases at AASLD 2026

Thu, 22 Oct 2026 08:01:11 -0400

Gilead Sciences (NASDAQ: GILD) will present 21 abstracts on primary biliary cholangitis (PBC) and chronic hepatitis delta virus (HDV) at The Liver Meeting 2026, hosted by the American Association for the Study of Liver Diseases (AASLD) from November 5–9 in Denver, Colorado.

A late-breaking oral presentation on November 8 will feature Phase 3 results from the IDEAL study, which evaluated the effect of Livdelzi (seladelpar) on composite alkaline phosphatase (ALP) normalization in adults with PBC who had lower levels of ALP elevation and were on or intolerant to ursodeoxycholic acid. Additional PBC data include five-year safety and efficacy findings from the

Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026

Thu, 22 Oct 2026 08:00:00 -0400

- Late-Breaking Phase 3 Data from the IDEAL Study Highlight the Impact of Livdelzi® on Composite Alkaline Phosphatase (ALP) Normalization and Other Markers of Disease Progression in Primary Biliary Cholangitis (PBC) -

- New Long-Term and Real-World Evidence in Hepatitis Delta Virus (HDV) Examine Combined Virologic and Biochemical Response with Hepcludex® -

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) will present new clinical and real-world evidence across primary biliary cholangitis (PBC) and chronic hepatitis delta virus (HDV) infection at The Liver Meeting® 2026, hosted by the American Association for the Study of Liver Diseases (AASLD),

Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026

Thu, 22 Oct 2026 08:00:00 -0400

- New Long-Term and Real-World Evidence in Hepatitis Delta Virus (HDV) Examine Combined Virologic and Biochemical Response with Hepcludex® -

Gilead Sciences (GILD) PT Raised to $172 at BofA Securities

Tue, 20 Oct 2026 04:59:28 -0400

BofA Securities analyst Tazeen Ahmad raised the price target on Gilead Sciences (NASDAQ: GILD) to $172.00 (from $168.00) while maintaining a Buy rating.

The analyst comments "GILD announced positive results from the phase 2 SWIFT study evaluating once-daily oral emvistegrast in moderate-to-severe UC. We are encouraged by the data, which showed benefit across clinical and objective measures of disease activity and, in our view, support a potentially differentiated profile combining competitive efficacy, oral convenience and favorable initial safety. Importantly, the profile appears to match the bar outlined in our recent KOL discussions, where physicians saw meaningful 1L opportunity if oral emvistegrast

Gilead Sciences (GILD) PT Raised to $172 at BofA Securities

Tue, 20 Oct 2026 04:59:28 -0400

BofA Securities analyst Tazeen Ahmad raised the price target on Gilead Sciences (NASDAQ: GILD) to $172.00 (from $168.00) while maintaining a Buy rating.

Gilead to present HIV and antiviral data at IDWeek 2026

Mon, 19 Oct 2026 08:00:55 -0400

Gilead Sciences (Nasdaq: GILD) will present 28 abstracts, including two oral presentations, at IDWeek 2026, scheduled for October 21-24 in Washington, D.C., according to a company statement.

The presentations cover HIV treatment, HIV prevention, and an investigational therapy for recurrent genital herpes. New sub-analyses from the Phase 3 ARTISTRY-1 and ARTISTRY-2 studies will examine outcomes with Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg) in patients with comorbidities including dyslipidemia, hypertension, diabetes mellitus, and renal impairment. Bixlenvo is approved in the U.S. as a once-daily single tablet regimen for virologically suppressed adults with HIV.

An oral presentation will feature real-world data on U.S. adoption

Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026

Mon, 19 Oct 2026 08:00:00 -0400

– Analyses of Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg) Examine Outcomes in People with HIV and Selected Comorbidities or Renal Impairment –

– Real-World Evidence Provides Insight into Early U.S. Adoption of Yeztugo® (lenacapavir) for HIV PrEP –

– Phase 1b Data Highlight Virologic Efficacy, Safety and Tolerability of Investigational GS-1179 for Recurrent Genital Herpes –

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its HIV and antiviral research and development programs at IDWeek 2026, taking place October 21-24 in Washington, D.C. The 28 presentations, including two oral presentations, will feature

Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026

Mon, 19 Oct 2026 08:00:00 -0400

– Analyses of Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg) Examine Outcomes in People with HIV and Selected Comorbidities or Renal Impairment –

– Real-World Evidence Provides Insight into Early U.S. Adoption of Yeztugo® (lenacapavir) for HIV PrEP –

– Phase 1b Data Highlight Virologic Efficacy, Safety and Tolerability of Investigational GS-1179 for Recurrent Genital Herpes –

Form 4 GILEAD SCIENCES, INC. For: Oct 15 Filed by: Dickinson Andrew D

Fri, 16 Oct 2026 16:17:00 -0400

si-local-file:///var/storage/secattach/20261016/27198143.html

Form 4 GILEAD SCIENCES, INC. For: Oct 15 Filed by: Mercier Johanna

Fri, 16 Oct 2026 16:12:00 -0400

si-local-file:///var/storage/secattach/20261016/27198063.html

Form 144 GILEAD SCIENCES, INC. Filed by: Dickinson Andrew D

Thu, 15 Oct 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20261015/27193666.html

Form 144 GILEAD SCIENCES, INC. Filed by: Mercier Johanna

Thu, 15 Oct 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20261015/27193676.html

Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

Thu, 15 Oct 2026 16:05:00 -0400

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2026 financial results and guidance will be released on Thursday, October 29, 2026 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2026 financial results and provide a business update.

A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs

Gilead Sciences to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026

Thu, 15 Oct 2026 16:05:00 -0400

A live webcast will be available in the Investors section of www.gilead.com and will be archived there for one year.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs

Gilead Sciences (GILD) PT Raised to $164 at BofA Securities

Mon, 12 Oct 2026 06:17:39 -0400

BofA Securities analyst Tazeen Ahmad raised the price target on Gilead Sciences (NASDAQ: GILD) to $164.00 (from $162.00) while maintaining a Buy rating.

The analyst comments "We model 3Q Biktarvy sales of $3.922bn (cons: $3.908bn), Descovy $921mn (cons: $916mn), Kite $392mn (cons: $391mn), Trodelvy $467mn (cons: $467mn), Livdelzi $196mn (cons: $199mn) and Yeztugo $292mn (cons: $290mn). We look for continued Yeztugo launch progress, broader Livdelzi adoption post-IDEAL data and Trodelvy uptake following its 1L mTNBC expansion. We remain bullish on GILD’s growth outlook, with its leading HIV franchise and strong launch execution supporting sustained commercial momentum. Beyond HIV, we see meaningful

Gilead Sciences (GILD) PT Raised to $164 at BofA Securities

Mon, 12 Oct 2026 06:17:39 -0400

BofA Securities analyst Tazeen Ahmad raised the price target on Gilead Sciences (NASDAQ: GILD) to $164.00 (from $162.00) while maintaining a Buy rating.

Gilead Sciences (GILD) PT Raised to $126 at RBC Capital

Thu, 08 Oct 2026 08:26:34 -0400

RBC Capital analyst Brian Abrahams raised the price target on Gilead Sciences (NASDAQ: GILD) to $126.00 (from $123.00) while maintaining a Sector Perform rating.

Gilead Sciences (GILD) PT Raised to $170 at JPMorgan

Wed, 07 Oct 2026 08:36:25 -0400

JPMorgan analyst Chris Schott raised the price target on Gilead Sciences (NASDAQ: GILD) to $170.00 (from $160.00) while maintaining a Overweight rating.

Gilead Sciences (GILD) PT Lowered to $163 at Morgan Stanley

Wed, 07 Oct 2026 07:58:31 -0400

Morgan Stanley analyst Terence Flynn lowered the price target on Gilead Sciences (NASDAQ: GILD) to $163.00 (from $165.00) while maintaining a Overweight rating.

Gilead Sciences (GILD) PT Raised to $158 at Truist Securities

Wed, 07 Oct 2026 07:13:50 -0400

Truist Securities analyst Greg Renza raised the price target on Gilead Sciences (NASDAQ: GILD) to $158.00 (from $150.00) while maintaining a Buy rating.